Bioimpedance Analyzers Market is predicted to reach USD 0.82 billion at a CAGR of 10.50% during the forecast period 2023 to 2030

Market Research Future (MRFR) has published a half cooked research report on the “global Bioimpedance Analyzers Market” that contains information from 2023 to 2030.

The bioimpedance analyzers market is estimated to register a CAGR of 10.50% during the forecast period and is estimated to reach USD 0.82 billion by 2030.

Bioimpedance analysis (BIA) or bio-electrical impedance analysis is a method for figuring out a person's body composition or the proportion of body fat to muscular body mass. It also allows for the determination of fitness levels, bone weight, metabolic rate, percentage of hydration, and percentage of muscle tissue.

The increasing prevalence of lifestyle diseases, technological advancements, and initiatives by governments and private organizations to promote healthy lifestyles are propelling the market growth. However, inconsistency in the accuracy of different bioimpedance analyzers are expected to hamper the growth of the global market. Nevertheless, increasing fitness clubs along with sports rehabilitation centers is projected to create lucrative opportunities for market players.

Access Full Report @ https://www.marketresearchfuture.com/reports/bioimpedance-analyzers-market-11502

MRFR recognizes the following companies as the key players in the global bioimpedance analyzers market— Bioparhom (France), Akern (Italy), Biodynamics Corporation (US), Tanita Corporation (Japan), Biotekna (Italy), Omron Corporation (Japan), InBody (South Korea), EVOLT 360 (Australia), RJL Systems (US), and Fook Tin Group Holding Ltd (China).

Global Bioimpedance Analyzers Market Segment Analysis

The global bioimpedance analyzers market has been segmented based type, modality, application, and end user.

On the basis of type, the market is segmented into multi-frequency, single-frequency, and dual-frequency. The multi-frequency segment was attributed to holding the largest market share in 2022.

Based on modality, the global bioimpedance analyzers market has been segmented into wired bioimpedance and wireless bioimpedance. The wireless bioimpedance segment was expected to hold the largest market share in 2022.

Based on application, the global bioimpedance analyzers market has been segmented into whole-body measurement and segmental body measurement. The segmental body measurement segment was expected to hold the largest market share in 2022.

On the basis of the end user, the market is segmented into hospitals, fitness clubs and wellness centers, home users, and others. The fitness clubs and wellness centers segment are projected to have the largest market share during the forecast period.

Regional Analysis

The global bioimpedance analyzers market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe bioimpedance analyzers market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The bioimpedance analyzers market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World bioimpedance analyzers market comprises of Middle East, Africa, and Latin America.

The rising obesity rates, rising healthcare costs, growth in the number of fitness centers and health clubs, as well as a rising older population, are boosting the growth of the North America region. In addition, a research published in Nature Journals in April of 2021 estimated that 25% of Canadians had metabolic disorder syndromes. Furthermore, the high prevalence of metabolic disorders in this region is predicted to boost the demand for bioimpedance analyzers, supporting the market's growth.

Moreover, the Europe market has been persistently growing owing to rising prevalence of metabolic disorders, increasing government initiatives to encourage the adoption of healthy lifestyles, and rising technological advancements in the region.

Additionally, market factors, such as rising R&D activity and the development of emerging economies like China and India, the region offers lucrative opportunities for players in the bioimpedance analyzers market in the Asia-Pacific region are driving the region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The market factors such as rise in the prevalence of obesity across the region. On the other hand, the high cost associated with the equipment is expected to obstruct the market growth in the region.

Key Findings of the Study

• The global bioimpedance analyzers market is expected to reach USD 0.82 billion by 2030, at a CAGR of 10.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiac diseases, the increasing number of investigational compounds and ongoing preclinical trials in oncology in the Asia-Pacific region.


• Based on modality, the wireless bioimpedance segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.


• Bioparhom (France), Akern (Italy), Biodynamics Corporation (US), Tanita Corporation (Japan), Biotekna (Italy), Omron Corporation (Japan), InBody (South Korea), EVOLT 360 (Australia), RJL Systems (US), and Fook Tin Group Holding Ltd (China) are the key market players.